Article Information
History
- July 30, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Veronica Calvo1,3,
- Wei Zheng1,
- Kirk A. Staschke2,
- Julie Cheung1,
- Ana Rita Nobre1,
- Eduardo F. Farias1,3,
- Ari Nowacek3,
- Mark Mulvihill3,
- Alan C. Rigby3 and
- Julio A. Aguirre-Ghiso1,*
- 1Division of Hematology and Oncology, Department of Medicine and Department of Otolaryngology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 2Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA
- 3HiberCell, Inc, 619 West 54th Street, 8th Floor, New York, NY USA
- ↵*Corresponding author: julio.aguirre-ghiso{at}mssm.edu
Posted July 30, 2021.
PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
